NRX Pharmaceuticals (NRXP) EBT (2017 - 2026)

NRX Pharmaceuticals (NRXP) has reported EBT for 10 consecutive years, with -$6.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 80.77% year-over-year to -$6.7 million in Q2 2026; TTM through Jun 2026 was -$21.0 million, a 61.52% decrease from a year earlier, with the FY2025 full-year figure at -$16.9 million, up 1.89% from the prior year.
• EBT was -$6.7 million for Q2 2026 at NRX Pharmaceuticals, down from -$5.0 million in the prior quarter.
• Over five years, EBT peaked at -$2.4 million in Q4 2024 and troughed at -$15.7 million in Q1 2022.
• A 5-year average of -$6.3 million and a median of -$5.5 million in 2023 frame the typical range for EBT.
• The widest YoY moves for EBT: up 75.58% in 2022, down 8042.81% in 2022.
• Over 5 years, EBT stood at -$9.8 million in 2022, then surged by 54.79% to -$4.4 million in 2023, then soared by 44.97% to -$2.4 million in 2024, then tumbled by 117.92% to -$5.3 million in 2025, then decreased by 27.37% to -$6.7 million in 2026.
• The last three EBT figures came in at -$6.7 million (Q2 2026), -$5.0 million (Q1 2026), and -$5.3 million (Q4 2025), per Business Quant data.